Zacks Research Has Positive Forecast for CRSP Q2 Earnings
Equities researchers at Zacks Research upped their Q2 2025 earnings estimates for CRISPR Therapeutics in a report issued on ...
Could buying this gene-editing penny stock at $1 make me rich?
This writer digs into the CRISPR gene-editing space, asking whether one particular penny stock is worth taking a punt on in his ISA. The post Could buying this gene-editing penny stock at $1 make me ...